Skip to main content
SpringerLink
Log in

Prognostic Factors in Metastatic Renal Cell Carcinoma

  • Chapter
Renal Cell Carcinoma

Part of the book series: Current Clinical Oncology ((CCO))

  • 122 Accesses

Abstract

It is estimated that almost 30,000 persons were diagnosed with renal cell carcinoma (RCC) in 1998 and that 11,600 deaths were caused by this malignancy (1). If detected early, prior to metastasis, many patients can be cured surgically. The estimated 5-yr survival for patients with disease confined to the kidney (stages T1 and T2) is approximately 90–95% (2). However, once metastatic disease develops, the prognosis for long-term survival is poor, with estimated 5-yr survival of 0–20% (2). Unfortunately, approximately one-third of patients has metastatic disease on initial presentation (2), and therefore, effective treatment strategies for this disease are clearly needed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Landis SH, Murray T, Bolden C, and Wingo PA. Cancer statistics, Ca. Cancer J. Clin., 48 (1998) 6–29.

    Article  PubMed  CAS  Google Scholar 

  2. Linehane WM, Shipley WU, and Parkinson DR. Cancer of the kidney and ureter. In Cancer: Principles and Practice of Oncology. DeVita VT, Hellman S, and Rosenberg SA (eds.), 5th ed., Lippincott-Raven, Philadelphia, PA, 1997.

    Google Scholar 

  3. Bukowski RM, Rayman P, Uzzo R, Bloom T, Sandstrom K, Peereboom D, et al. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy, Clin. Cancer Res., 4 (1998) 2337–2347.

    PubMed  CAS  Google Scholar 

  4. Maldazys JD and deKernion JB. Prognostic factors in metastatic renal carcinoma, J. Urol., 136 (1986) 376–379.

    PubMed  CAS  Google Scholar 

  5. de Forges A, Rey A, Klink M, Ghosn M, Kramar A, and Droz J-P. Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis, Semin. Surg. Oncol., 4 (1988) 149–154.

    Article  PubMed  Google Scholar 

  6. Neves RJ, Zincke H, and Taylor WF. Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival, J. Urol., 139 (1988) 1173–1176.

    PubMed  CAS  Google Scholar 

  7. Elson PJ, Witte RS, and Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma, Cancer Res., 48 (1988) 7310–7313.

    PubMed  CAS  Google Scholar 

  8. Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2, Ann. Oncol., 3 (1992) 475–480.

    PubMed  CAS  Google Scholar 

  9. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, and Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up, J. Clin. Oncol., 11 (1993) 1368–1375.

    PubMed  CAS  Google Scholar 

  10. Fosså, SD, Kramar A, and Droz J-P. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-a, Eur. J. Cancer, 30 (1994) 1310–1314.

    Article  Google Scholar 

  11. Canobbio L, Rubagotti A, Miglietta L, Cannata D, Curotto A, Amoroso D, and Boccardo F. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-a, J. Cancer Res. Clin. Oncol., 121 (1995) 753–756.

    Article  PubMed  CAS  Google Scholar 

  12. Mani S, Todd MB, Katz K, and Poo W-J. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers, J. Urol., 154 (1995) 35–40.

    Article  PubMed  CAS  Google Scholar 

  13. Citterio G, Bertuzzi A, Tresoldi M, Galli L, Di Lucca G, Scaglietti U, and Rugarli C. Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients, Eur. Urol., 31 (1997) 286–291.

    PubMed  CAS  Google Scholar 

  14. Wittke F, Hoffman R, Buer J, Dallmann I, Oevermann K, Sel S, et al. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma, Br. J. Cancer, 79 (1999) 1182–1184.

    Article  PubMed  CAS  Google Scholar 

  15. Hoffmann R, Franzke A, Buer J, Sel S, Oevermann K, Duensing A, et al. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma, Br. J. Cancer, 79 (1999) 1742–1745.

    Article  PubMed  CAS  Google Scholar 

  16. Fyfe G, Fisher R, Rosenberg SA, Sznol M, Parkinson D, and Louis AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy, J. Clin. Oncol., 13 (1995) 688–696.

    PubMed  CAS  Google Scholar 

  17. Klugo RC, Detmers M, Stiles RE, Talley RW, and Cerny JC. Aggressive versus conservative management of stage IV renal cell carcinoma, J. Urol., 118 (1977) 244–246.

    PubMed  CAS  Google Scholar 

  18. Al-Sarraf M, Eyre H, Bonnet J, Saiki R, Gagliano R, Pugh R, et al. Study of tamoxifen in metastatic renal cell carcinoma and the influence of certain prognostic factors: a southwest oncology group study, Cancer Treat Rep., 65 (1981) 447–451.

    PubMed  CAS  Google Scholar 

  19. Lopez-Hänninen E, Kirchner H, and Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients, J. Urol., 155 (1996) 19–25.

    Article  PubMed  Google Scholar 

  20. Ljungberg B, Grankvist K, and Rasmuson T. Serum acute phase reactants and prognosis in renal cell carcinoma, Cancer, 76 (1995) 1435–1439.

    Article  PubMed  CAS  Google Scholar 

  21. Jakobsen EB, Eickhoff JH, Andersen JP, and Ottesen M. Prognosis after nephrectomy for renal cell carcinoma, Scand. J. Urol. Nephrol., 28 (1994) 229–236.

    PubMed  CAS  Google Scholar 

  22. deKernion JB and Berry D. The diagnosis and treatment of renal cell carcinoma, Cancer, 45 (1980) 1947–1956.

    PubMed  CAS  Google Scholar 

  23. deKernion JB, Ramming KP, and Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis, J. Urol., 120 (1978) 148–152.

    PubMed  CAS  Google Scholar 

  24. Guinan PD, Vogelzang NJ, Fremgen AM, Chmiel JS, Sylvester JL, Sener SF, and Imperato JP. Renal cell carcinoma: tumor size, stage and survival, J. Urol., 153 (1995) 901–903.

    Article  PubMed  CAS  Google Scholar 

  25. Fahn H-J, Lee Y-H, Chen M-T, Huang J-K, Chen K-K, and Chang LS. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma, J. Urol., 145 (1991) 248–250.

    PubMed  CAS  Google Scholar 

  26. Rasmuson T, Björk GR, Hietala S-O, Stenling R, and Ljungberg B. Excretion of pseudouridine as an independent prognostic factor in renal cell carcinoma, Acta Oncologica, 30 (1991) 11–15.

    Article  PubMed  CAS  Google Scholar 

  27. Rasmuson T, Grankvist K, and Ljungberg B. Serum y-enolase and prognosis of patients with renal cell carcinoma, Cancer, 72 (1993) 1324–1328.

    Article  PubMed  CAS  Google Scholar 

  28. Seaman E, Goluboff ET, Ross S, and Sawczuk IS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma, Urology, 48 (1996) 692–695.

    Article  PubMed  CAS  Google Scholar 

  29. Rasmuson T, Grankvist K, and Ljungberg B. Serum (32-microglobulin and prognosis of patients with renal cell carcinoma, Acta Oncologica, 35 (1996) 479–482.

    Article  PubMed  CAS  Google Scholar 

  30. Nakano E, Kondoh M, Okatani K, Seguchi T, and Sugao H. Flow cytometric analysis of nuclear DNA content of renal cell carcinoma correlated with histologic and clinical features, Cancer, 72 (1993) 1319–1323.

    Article  PubMed  CAS  Google Scholar 

  31. Lanigan D, McLean PA, Murphy DM, Donovan MG, Curran B, and Leader M. Ploidy and prognosis in renal carcinoma, Br. J. Urol., 71 (1993) 21–24.

    Article  PubMed  CAS  Google Scholar 

  32. Ljungberg B, Mehle C, Stenling R, and Roos G. Heterogeneity in renal cell carcinoma and its impact on prognosis—a flow cytometric study, Br. J. Cancer, 74 (1996) 123–127.

    Article  PubMed  CAS  Google Scholar 

  33. Eskelinen M, Lipponen P, and Nordling S. Prognostic evaluation of DNA flow cytometry and histomorphological criteria in renal cell carcinoma, Anticancer Res., 15 (1995) 2279–2284.

    PubMed  CAS  Google Scholar 

  34. Ruiz JL, Hernández M, Martinez J, Vera C, and Jimenez-Cruz JF. Value of morphometry as an independent prognostic factor in renal cell carcinoma, Eur. Urol., 27 (1995) 54–57.

    PubMed  CAS  Google Scholar 

  35. van der Poel HG, Mulders PFA, Oosterhof GON, Schaafsma HE, Hendriks JCM, Schalken JA, and Debruyne FMJ. Prognostic value of karyometric and clinical characteristics in renal cell carcinoma, Cancer, 72 (1993) 2667–2674.

    Article  PubMed  Google Scholar 

  36. Delahunt B, Becker RL, Bethwaite PB, and Ribas JL. Computerized nuclear morphometry and survival in renal cell carcinoma: comparison with other prognostic indicators, Pathology, 26 (1994) 353–358.

    Article  PubMed  CAS  Google Scholar 

  37. Artacho-Pérula E, Roldán-Villalobos R, Martínez-Cuevas JF, and López-Rubio F. Nuclear quantitative grading by discriminant analysis of renal cell carcinoma samples. A patient survival evaluation, J. Pathol., 173 (1994) 105–114.

    Article  PubMed  Google Scholar 

  38. Fujikawa K, Sasaki M, Aoyama T, and Itoh T. Role of volume weighted mean nuclear volume for predicting disease outcome in patients with renal cell carcinoma, J. Urol., 157 (1997) 1237–1241.

    Article  PubMed  CAS  Google Scholar 

  39. Blay J-Y, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of inteleukin 6 as a prognosis factor in metastatic renal cell carcinoma, Cancer Res., 52 (1992) 3317–3322.

    PubMed  CAS  Google Scholar 

  40. Ljungberg B, Grankvist K, and Rasmuson T. Serum inteleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma, Eur. J. Cancer, 33 (1997) 1794–1798.

    Article  PubMed  CAS  Google Scholar 

  41. Stadler WM, Richards JM, and Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator, J. Natl. Cancer Inst., 84 (1992) 1835, 1836.

    Google Scholar 

  42. Knoefel B, Nuske K, Steiner T, Junker K, Kosmehl H, Rebstock K, et al. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-(31 in primary cultures and modulate T-lymphocyte blast transformation, J. Interferon Cytokine Res., 17 (1997) 95–102.

    Article  PubMed  CAS  Google Scholar 

  43. Matsumoto T, Furukawa A, Sumiyoshi Y, Akiyama K-Y, Kanayama H-O, and Kagawa S. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma, Urology, 51 (1998) 145–149.

    Article  PubMed  CAS  Google Scholar 

  44. Göhring B, Riemann D, Rebmann U, Heynemann H, Schabel J, and Langner J. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-a-2 in combination with 5-FU, Urol. Res., 24 (1996) 297–303.

    Article  PubMed  Google Scholar 

  45. Arima K, Nakagawa M, Yanagawa M, Sugimura Y, Tochigi H, and Kawamura J. Prognostic factors of peripheral blood lymphocyte subsets in patients with renal cell carcinoma, Urol. Int., 57 (1996) 5–10.

    Article  PubMed  CAS  Google Scholar 

  46. Delahunt B, Bethwaite PB, Thornton A, and Ribas JL. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling, Cancer, 75 (1995) 2714–2719.

    Article  PubMed  CAS  Google Scholar 

  47. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kühn R, and Wittekind CW. Prognostic value of ploidy and proliferation markers in renal cell carcinoma, Cancer, 77 (1996) 164–171.

    Article  PubMed  CAS  Google Scholar 

  48. Moch H, Sauter G, Gasser TC, Buchholz N, Bubendorf L, Richter J, et al. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma, Urol. Res., 25 (Suppl 1) (1997) 25–30.

    Article  Google Scholar 

  49. Lipponen P, Eskelinen M, Hietala K, and Syrjänen K. Expression of proliferating cell nuclear antigen (PC 10), p53 protein and c-erbB-2 in renal adenocarcinoma, Int. J. Cancer, 57 (1994) 275–280.

    Article  PubMed  CAS  Google Scholar 

  50. Cronin KJ, Williams NN, Kerin MJ, Creagh TA, Dervan PA, Smith JM, and Fitzpatrick JM. Proliferating cell nuclear antigen: a new prognostic indicator in renal cell carcinoma, J. Urol., 152 (1994) 834–836.

    PubMed  CAS  Google Scholar 

  51. Yang AH, Wang TY, and Liu HC. Comparative study of the prognostic value of nuclear grade and silver binding nucleolar organizer region in renal cell carcinomas, J. Pathol., 166 (1992) 157–161.

    Article  PubMed  CAS  Google Scholar 

  52. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T, and Kawanishi M. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma, Eur. Urol., 31 (1997) 73–80.

    PubMed  CAS  Google Scholar 

  53. Uhlman DL, Nguyen PL, Manivel JC, Aeppli D, Resnick JM, Fraley EE, et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma, J. Natl. Cancer Inst., 86 (1994) 1470–1475.

    Article  PubMed  CAS  Google Scholar 

  54. Bot FJ, Godschalk JCJ, Krishnadath KK, van der Kwast THM, and Bosman FT. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters, Int. J. Cancer, 57 (1994) 634–637.

    Article  PubMed  CAS  Google Scholar 

  55. Lipponen P, Eskelinen M, and Syrjänen K. Expression of tumour-suppressor gene Rb, apoptosissuppressing protein Bcl-2, and c-Myc have no independent prognostic value in renal cell adenocarcinoma, Br. J. Cancer, 71 (1995) 863–867.

    Article  PubMed  CAS  Google Scholar 

  56. Uhlman DL, Nguyen P, Manivel JC, Zhang G, Hagen K, Fraley E, et al. Epidermal growth factor receptor and transforming growth factor a expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis, Clin. Cancer Res., 1 (1995) 913–920.

    PubMed  CAS  Google Scholar 

  57. Moch H, Sauter G, Buchholz N, Gasser TC, Bubendorf L, Waldman FM, and Mihatsch MJ. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma, Hum. Pathol., 28 (1997) 1255–1259.

    Article  PubMed  CAS  Google Scholar 

  58. Rasmuson T, Grankvist K, and Ljungberg B. Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma, Br. J. Cancer, 75 (1997) 1674–1677.

    Article  PubMed  CAS  Google Scholar 

  59. Katagiri A, Watanabe R, and Tomita Y. E-cadherin expression in renal cell cancer and its significance in metastasis and survival, Br. J. Cancer, 71 (1995) 376–379.

    Article  PubMed  CAS  Google Scholar 

  60. Anastassiou G, Duensing S, Steinhoff G, Zorn U, Grosse J, Dallmann I, et al. Platelet endothelial cell adhesion molecule-1 (PECAM-1): a potential prognostic marker involved in leukocyte infiltration of renal cell carcinoma, Oncology, 53 (1996) 127–132.

    Article  PubMed  CAS  Google Scholar 

  61. Moch H, Presti JC, Sauter G, Buchholz N, Jordan P, Mihatsch MJ, and Waldman FM. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma, Cancer Res., 56 (1996) 27–30.

    PubMed  CAS  Google Scholar 

  62. Elfving P, Mandahl N, Lundgren R, Limon J, Bak-Jensen E, Fernö, M, et al. Prognostic implications of cytogenetic findings in kidney cancer, Br. J. Urol., 80 (1997) 698–706.

    Article  PubMed  CAS  Google Scholar 

  63. Wu S-Q, Hafez GR, Xing W, Newton M, Chen X-R, and Messing E. The correlation between the loss of chromosome 14q with histologic tumor grade, pathologic stage, and outcome of patients with non-papillary renal cell carcinoma, Cancer, 77 (1996) 1154–1160.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Paul J. Elson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Experimental Therapeutics, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    Ronald M. Bukowski MD (Director) (Director)

  2. Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA

    Andrew C. Novick MD (Chairman) (Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Elson, P.J. (2000). Prognostic Factors in Metastatic Renal Cell Carcinoma. In: Bukowski, R.M., Novick, A.C. (eds) Renal Cell Carcinoma. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-229-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-229-6_9

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6401-7

  • Online ISBN: 978-1-59259-229-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation